MAI Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$650K Buy
+1,289
New +$681K ﹤0.01% 1138
2026
Q2
– Sell
-130
Closed -$68.1K – 3636
2026
Q1
$68.1K Buy
130
+63
+94% +$30.1K ﹤0.01% 2049
2025
Q4
$39K Buy
67
+61
+1,017% +$31.2K ﹤0.01% 2153
2025
Q3
$2.75K Sell
6
-6
-50% -$2.24K ﹤0.01% 3228
2025
Q2
$3.63K Buy
12
+5
+71% +$1.49K ﹤0.01% 3193
2025
Q1
$2.32K Buy
7
+3
+75% +$986 ﹤0.01% 2947
2024
Q4
$1.24K Buy
+4
New +$1.12K ﹤0.01% 3142

Other funds holding MDGL

MAI Capital Management's MDGL Position: Q3 2026 in Review

MAI Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 1,289 shares worth $650K. The stake represents ﹤0.01% of the portfolio and ranks #1138 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in MDGL as recently as Q1 2026.

MAI Capital Management first reported a position in MDGL in Q4 2024 and has held it in 7 quarters since. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • MAI Capital Management held 1,289 shares of Madrigal Pharmaceuticals worth $650K as of Q3 2026.
  • Madrigal Pharmaceuticals was a new MAI Capital Management position in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q3 2026, its #1138 holding.
  • MAI Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on MAI Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.